Skip to content

Company · founded 1999

Eloxx Pharmaceuticals (United States)

Waltham, United States · eloxxpharma.com

Manage this page

Citations, last 5 years: 284
Works, last 5 years: 21
h-index: 25
Scientists listed: 5
Grants since 2016: 6

Grants received

2022–2025 · cooperative agreement · U01

Development of TNX-1300 (Double Mutant Cocaine Esterase) for the Treatment of Life-Threatening Cocaine Intoxication

Gregory M Sullivan · Eloxx Pharmaceuticals (United States) · funded by National Institutes of Health

$2.6MForensic Toxicology and Drug Analysis

2022–2025 · cooperative agreement · U01

Development of TNX-1300 (Double Mutant Cocaine Esterase) for the Treatment of Life-Threatening Cocaine Intoxication

Gregory M Sullivan · Eloxx Pharmaceuticals (United States) · funded by National Institutes of Health

$2MForensic Toxicology and Drug Analysis

2022–2025 · cooperative agreement · U01

Development of TNX-1300 (Double Mutant Cocaine Esterase) for the Treatment of Life-Threatening Cocaine Intoxication

Gregory M Sullivan · Eloxx Pharmaceuticals (United States) · funded by National Institutes of Health

$605.8k

2020–2023 · research · R41

New Inhibitors of HIV latency reactivation

Jonathan Karn · Eloxx Pharmaceuticals (United States) · funded by National Institutes of Health

$298.4k

2020–2022 · research · R41

New Inhibitors of HIV latency reactivation

Jonathan Karn · Eloxx Pharmaceuticals (United States) · funded by National Institutes of Health

$298.4k

2020–2023 · research · R41

Small molecule inhibitors of oncogenic miR-21

George A. Calin · Eloxx Pharmaceuticals (United States) · funded by National Institutes of Health

$249.1kMicroRNA in disease regulation